Expression and function of ABCG2 and XIAP in glioblastomas

Area of Science:

• Neuro-oncology
• Cancer Biology
• Molecular Medicine

Background:

• Glioblastoma (GBM) frequently recurs despite multimodal treatments.
• Therapy resistance and cancer cell survival mechanisms in GBM remain incompletely understood.
• Glioma stem cells (GSCs) exhibit enhanced resistance to therapies.

Purpose of the Study:

• To identify novel therapeutic targets in GBM by examining proteins linked to therapy resistance.
• To investigate the expression and functional role of ABCG2 and XIAP in GBM and GSCs.
• To evaluate the potential of targeting ABCG2 as a therapeutic strategy.

Main Methods:

• Immunohistochemistry was used to measure the expression of eight proteins in 50 GBM samples.
• Patient survival data was analyzed in correlation with protein expression levels.
• Patient-derived GBM tumorspheres were treated in vitro with small molecule inhibitors of ABCG2.

Main Results:

• High protein expression of ABCG2 (BCRP) and XIAP was associated with significantly worse patient survival (HR=2.35 for ABCG2, HR=2.65 for XIAP).
• GSCs express high levels of ABCG2 and XIAP.
• Inhibitors targeting ABCG2 (Ko143, fumitremorgin) significantly reduced GSC self-renewal in vitro.

Conclusions:

• ABCG2 and XIAP are potential prognostic indicators for GBM patient survival.
• Targeting ABCG2 presents a promising therapeutic strategy for overcoming GBM therapy resistance.
• Further research into ABCG2 and XIAP functions may reveal new avenues for GBM treatment.